Document is current
Any future updates will be listed below
-
Authors
Sun, Le https://orcid.org/0009-0002-4573-0237
Rodriguez, Larry
Pankow, Sandra https://orcid.org/0000-0003-3213-9886
Diedrich, Jolene
Qin, Ke
Zhang, Jianan
Wu, Xu
Wu, Peng https://orcid.org/0000-0002-5204-0229
Yates, John R. III https://orcid.org/0000-0001-5267-1672
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL165168)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM139643)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA290785)
- License Information
-
More Information
Article History
Received: 2 February 2026
Accepted: 29 May 2026
First Online: 9 June 2026
Competing interests
: Dr. Xu Wu has a financial interest in Tasca Therapeutics, which is developing small-molecule modulators of TEAD palmitoylation and transcription factors. Dr. Wu’s interests were reviewed and are managed by Mass General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.
